SmartBrief > Telecommunications > CTAM SmartBrief > Pfizer Inc. Profile

Pfizer Inc.

News and overview for Pfizer Inc.

Immunovaccine Licenses Vaccine Platform to Pfizer Animal Health [Press Release]
MarketWire | 1 minute ago
HALIFAX, NOVA SCOTIA -- (Marketwire) -- 11/23/09 -- Immunovaccine Inc. (TSX VENTURE: IMV), a vaccine development company, today announced the signing of an exclusive, worldwide license agreement with Pfizer Animal Health for Immunovaccine's patented vaccine delivery technology. Pfizer Animal Health said it plans to develop enhanced cattle vaccines incorporating Immunovaccine's technology. Under the terms of the agreement, which were not disclosed, Immunovaccine will receive upfront signing f...


Pfizer reportedly to sell generic drugs in Japan - MarketWatch
MarketWatch | 4 days 14 hours 42 minutes ago
The U.S. company's Japanese unit plans to set up a division on Dec. 1 dedicated to drugs whose patents have expired, Japanese business daily Nikkei reported.


Pfizer Submits New Pediatric Data For Lipitor (Atorvastatin) To The European Medicines Agency (EMEA) [Press Release]
Business Wire | 5 days 7 hours 29 minutes ago
Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission.


FDA Advisory Committee Finds Data Support the Safety and Effectiveness of Prevnar 13 Vaccine for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children [Press Release]
Business Wire | 4 days 16 hours 20 minutes ago
Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children. The Company is seeking an indication for active...


Pfizer reports 26% higher profit, but lower sales - MarketWatch
MarketWatch | 34 days 4 hours 24 minutes ago
The world's largest drug maker posted net income of $2.88 billion, or 43 cents a share, compared with $2.28 billion, or 34 cents a share, for the same quarter in 2008.


Pfizer subsidiary hit with record fine - MarketWatch
MarketWatch | 36 days 23 hours 8 minutes ago
Pfizer previously agreed to pay an additional $1 billion plus interest to settle civil allegations that it "fraudulently promoted and marketed Bextra, as well as three other drugs in its portfolio, Geodon, an anti-psychotic drug, Zyvox, and antibiotic, and Lyrica, and anti-epileptic drug," the Justice Department said.


Pfizer, Merck may feel pressure from generics - MarketWatch
MarketWatch | 38 days 6 hours 12 minutes ago
This earnings season will also mark the end of an era for the industry titans, as both are in the final phases of major mergers that aimed at refueling their drug pipelines and stoking profits. On Oct. 15, Pfizer is slated to complete its $68 billion takeover of rival Wyeth. Merck is expected to close on its $41 billion acquisition of Schering-Plough Corp. by the end of the quarter.


Merck, Pfizer, J&J lead drug stocks higher - MarketWatch
MarketWatch | 19 days 37 minutes ago
Shares of Merck /quotes/comstock/13*!mrk/quotes/nls/mrk (MRK 32.14, +1.47, +4.79%) were up almost 3% to $41.46.


Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases [Press Release]
Business Wire | 5 days 2 hours 59 minutes ago
Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.


Pfizer gains on results as Biogen Idec retreats - MarketWatch
MarketWatch | 34 days 1 hour 44 minutes ago
Shares of Pfizer /quotes/comstock/13*!pfe/quotes/nls/pfe (PFE 18.20, +0.22, +1.22%) traded up nearly 2% at $18.29.


Drug stocks decline; Pfizer rises on earnings - MarketWatch
MarketWatch | 34 days 2 hours 24 minutes ago
European shares choppy amid earnings, data





 1  2  3  4  5  6  7  8  9 ...   Next >

4607 Results

Sign up for CTAM SmartBrief



Designed specifically for cable and broadband executives like you, SmartBrief from CTAM is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more

Company Overview


Company: Pfizer Inc.
Industry: Pharmaceuticals Manufacturers
Website: http://www.pfizer.com

Pfizer pfabricates pfarmaceuticals pfor quite a pfew inpfirmities. The company is the world's largest research-based pharmaceuticals firm. Its best-known products include erectile dysfunction therapy Viagra, pain management drug Celebrex, high-blood-pressure therapy Norvasc, and cholesterol-lowering Lipitor. Pfizer also keeps Fluffy and Fido in mind with its animal health products, including Revolution (antiparasitic). The company markets its pharmaceuticals directly to health care providers and patients; most of its sales are conducted through wholesalers including McKesson and Cardinal Health. Pfizer acquired pharma rival Wyeth in a $68 billion deal in 2009.


Key Numbers

Sales in U.S. Dollars (mil.) 48,296 (2008)
One-year % Growth in Sales -0.3 (2008)
Net Income in U.S. Dollars (mil.) 8,104 (2008)
One-year % Growth in Net Income -0.5 (2008)
Number of Employees 81,800 (2008)
One-year % Growth in Number of Employees -5.5 (2008)
Fiscal Year-End December